Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05346952 | A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | unknown | Phase 3 | 390 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT03679936 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions and Differentiating Multiple Primary Lung Cancer From Intrapulmonary Metastases of Non-small Cell Lung Cancer | unknown | — |
| 120 |
| Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER |
| 1 |
| Apr 25, 2022 |
| clinicaltrials |
| NCT04948047 | Breath Combined With CT for Diagnoses of Pulmonary Nodules | unknown | — | 900 | Peking University People's HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT01470716 | Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations | unknown | Phase 2 | 26 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03612154 | Study of Lorlatinib in ROS1 Rearranged NSCLC | unknown | Phase 2 | 35 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT03808480 | Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% | unknown | Phase 2 | 22 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04040361 | Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY) | unknown | Phase 2 | 24 | Masahiro TsuboiOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05314296 | Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy(TRUST) | unknown | — | 70 | N.N. Blokhin National Medical Research Center of OncologyOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05306847 | Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer | unknown | Phase 2 | 93 | Peking Union Medical College HospitalOTHER | 0 | Apr 1, 2022 | clinicaltrials |
| NCT04325763 | A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 315 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05236608 | A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC(ADIVO Lung) | unknown | Phase 1 / Phase 2 | 53 | National University Hospital, SingaporeOTHER | 1 | Mar 25, 2022 | clinicaltrials |
| NCT04828850 | Preoperative Lymph Node Staging With EBUS-TBNA in Clinical N0 Non Small-cell Lung Cancer | unknown | N/A | 50 | European Institute of OncologyOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT05287386 | A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy | unknown | Phase 2 | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT05284994 | TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 160 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 17, 2022 | clinicaltrials |
| NCT05279521 | The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer. | unknown | N/A | 104 | National Taiwan University HospitalOTHER | 0 | Mar 15, 2022 | clinicaltrials |
| NCT01951469 | Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer | unknown | Phase 3 | 160 | Sun Yat-sen UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT04690686 | Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 24 | Immunicom IncINDUSTRY | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05267392 | Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy(IDEAR) | unknown | Phase 1 / Phase 2 | 30 | Instituto Portugues de Oncologia, Francisco Gentil, PortoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04956146 | Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | unknown | Phase 2 | 46 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02607592 | A Prospective Multi-center Phase III Randomized Controlled Trial(NACA) | unknown | Phase 3 | 293 | Sun Yat-sen UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT05254132 | Artificial Intelligence for Help Non-Small Cell Lung Cancer: Measure Cancer Biology and Treatment Response Via Imaging(SALMON) | unknown | — | 1,000 | OncoRadiomicsINDUSTRY | 0 | Feb 24, 2022 | clinicaltrials |
| NCT05252065 | Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer | unknown | — | 40 | Guizhou Medical UniversityOTHER | 0 | Feb 23, 2022 | clinicaltrials |
| NCT05252091 | An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC | unknown | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 23, 2022 | clinicaltrials |
| NCT03801200 | Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC | unknown | Phase 2 | 90 | Hubei Cancer HospitalOTHER | 1 | Feb 8, 2022 | clinicaltrials |
| NCT05137912 | Neoadjuvant Immunotherapy in Advanced NSCLC | unknown | — | 10 | Power Life Sciences Inc.INDUSTRY | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05223595 | A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC | unknown | Phase 1 | 42 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05218759 | Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC | unknown | N/A | 30 | Shanghai Chest HospitalOTHER | 0 | Feb 1, 2022 | clinicaltrials |
| NCT05210946 | A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients | unknown | N/A | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT05207904 | Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases | unknown | Phase 2 | 41 | Sun Yat-sen UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05209256 | Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC | unknown | Phase 2 / Phase 3 | 90 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05204628 | A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib | unknown | Phase 3 | 238 | Xuanzhu Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT01024829 | Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC(PET Boost) | unknown | N/A | 150 | The Netherlands Cancer InstituteOTHER | 5 | Jan 21, 2022 | clinicaltrials |
| NCT04595734 | Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors. | unknown | — | 500 | Western Sydney Local Health DistrictOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05065398 | A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation | unknown | Phase 2 | 20 | Shanghai Henlius BiotechINDUSTRY | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05165355 | Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma(ATHEM) | unknown | Phase 2 | 90 | Tongji UniversityOTHER | 1 | Jan 18, 2022 | clinicaltrials |
| NCT05192681 | Tislelizumab as Cross-line Treatment for Advanced NSCLC | unknown | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT05176067 | Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastatic NSCLC | unknown | N/A | 88 | Guizhou Medical UniversityOTHER | 0 | Jan 4, 2022 | clinicaltrials |
| NCT05177497 | SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC | unknown | Phase 2 | 19 | Shanghai Chest HospitalOTHER | 0 | Jan 4, 2022 | clinicaltrials |
| NCT04025424 | Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)(ICIPRESIST19) | unknown | — | 350 | Russian Academy of Medical SciencesOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05170581 | Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Dec 28, 2021 | clinicaltrials |
| NCT05167604 | Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC | unknown | — | 150 | Tang-Du HospitalOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT05167851 | The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer | unknown | Phase 2 | 68 | Yonsei UniversityOTHER | 1 | Dec 22, 2021 | clinicaltrials |
| NCT02743923 | Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer | unknown | Phase 3 | 203 | The Netherlands Cancer InstituteOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05157503 | Treatment of Patients With Stage III Non-small Cell Lung Cancer in Russia" | unknown | — | 1 | Autonomous Non-Profit Organization National Society of Onco-PulmonologistsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT05157542 | Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC | unknown | Phase 1 | 9 | Juan LI, MDOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT04989322 | Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC | unknown | Phase 2 | 46 | Dr Joanne CHIUOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05141786 | A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC). | unknown | Phase 2 | 100 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 2, 2021 | clinicaltrials |
| NCT02897479 | A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer | unknown | Phase 2 | 76 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 30, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Apr 26, 2022source: clinicaltrials